Showing results (271-280 of 278) with videos related to
Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 278 results.
Science Immunology|July 16, 2021
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primatesMaria Pino, Talha Abid, Susan Pereira Ribeiro, et al.Science (New York, N.Y.)|August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesWilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.JCI Insight|December 13, 2016
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaquesKan Luo, Hua-Xin Liao, Ruijun Zhang, et al.Nature Medicine|May 31, 2016
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisitionMonica Vaccari, Shari N Gordon, Slim Fourati, et al.Ebiomedicine|September 5, 2024
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control studyAvi Kenny, Janine van Duijn, One Dintwe, et al.Iscience|February 8, 2021
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidatesIsabela Silva de Castro, Giacomo Gorini, Rosemarie Mason, et al.Nature Communications|October 6, 2025
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIVNonhlanhla N Mkhize, Bo Zhang, Caroline Brackett, et al.Nature|April 1, 2022
Defining the risk of SARS-CoV-2 variants on immune protectionMarciela M DeGrace, Elodie Ghedin, Matthew B Frieman, et al.Pageof 28